This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Multiple Sclerosis - Current And Future Players

NEW YORK, April 11, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - Current and Future Players

PharmaPoint: Multiple Sclerosis - Current and Future Players

SummaryGlobalData has released its pharma report, "PharmaPoint: Multiple Sclerosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Sclerosis Market. The report identifies and analyses the key companies shaping and driving the global Multiple Sclerosis market. The report provides insight into the competitive Multiple Sclerosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope- Investigation of current and future market competition for Multiple Sclerosis- Competitor assessment- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.- Strategic assessment of the Multiple Sclerosis sector through market impact analysis, future market scenario and company analysis

Reasons to buy- Gain a high level view of the trends shaping and driving the Multiple Sclerosis Market- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.- Create an effective counter-strategy to gain a competitive advantage against those currently in the market- What's the next big thing in the global Multiple Sclerosis market landscape? Identify, understand and capitalize

Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Related Reports 93 Market Outlook 113.1 Global Markets 113.1.1 Forecast 113.1.2 Drivers and Barriers – Global Issues 134 Current and Future Players 174.1 Overview 174.2 Trends in Corporate Strategy 194.3 Company Profiles 214.3.1 Biogen Idec 214.3.2 Teva Pharmaceutical Industries 244.3.3 Merck Serono (EMD Serono) 274.3.4 Sanofi 304.3.5 Bayer HealthCare Pharmaceuticals 334.3.6 Novartis International 354.3.7 Hoffmann-La Roche 384.3.8 GlaxoSmithKline 405 Appendix 425.1 Bibliography 425.2 Abbreviations 425.3 Methodology 435.4 Forecasting Methodology 435.4.1 Diagnosed MS patients 435.4.2 Percent Drug-Treated Patients 445.4.3 Drugs Included in Each Therapeutic Class 445.4.4 Launch and Patent Expiry Dates 455.4.5 General Pricing Assumptions 465.4.6 Individual Drug Assumptions 475.4.7 Generic Erosion 505.4.8 Pricing of Pipeline agents 515.5 Physicians and Specialists Included in This Report 525.6 Primary Research – Prescriber Survey 535.7 About the Authors 535.7.1 Analysts 535.7.2 Global Head of Healthcare 545.8 About GlobalData 555.9 Contact Us 555.10 Disclaimer 55

List of TablesTable 1: Global Sales Forecasts ($m) for Multiple Sclerosis, 2012–2022 12Table 2: Global Multiple Sclerosis Market – Drivers and Barriers, 2012 13Table 3: Key Companies in the Multiple Sclerosis Market, 2012 18Table 4: Biogen's Multiple Sclerosis Portfolio Assessment, 2012 22Table 5: Biogen SWOT Analysis, 2012 23Table 6: Teva's Multiple Sclerosis Portfolio Assessment, 2012 25Table 7: Teva SWOT Analysis, 2012 26Table 8: Merck's Multiple Sclerosis Portfolio Assessment, 2012 28Table 9: Merck SWOT Analysis, 2012 29Table 10: Sanofi's Multiple Sclerosis Portfolio Assessment, 2012 31Table 11: Sanofi SWOT Analysis, 2012 32Table 12: Bayer's Multiple Sclerosis Portfolio Assessment, 2012 34Table 13: Bayer SWOT Analysis, 2012 34Table 14: Novartis' Multiple Sclerosis Portfolio Assessment, 2012 36Table 15: Novartis SWOT Analysis, 2012 37Table 16: Roche's Multiple Sclerosis Portfolio Assessment, 2012 39Table 17: Roche SWOT Analysis, 2012 39Table 18: GlaxoSmithKiline's Multiple Sclerosis Portfolio Assessment, 2012 41Table 19: GlaxoSmithKline SWOT Analysis, 2012 41Table 20: Key Launch Dates 45Table 21: Key Patent Expiries 45Table 22: Physicians Surveyed, By Country 53

List of FiguresFigure 1: Global Market Sales for Multiple Sclerosis by Region, 2012–2022 13Figure 2: Company Portfolio Gap Analysis in Multiple Sclerosis, 2012–2022 20

Companies MentionedBiogen IdecTeva Pharmaceutical IndustriesMerck Serono (EMD Serono)SanofiBayer HealthCare PharmaceuticalsNovartis InternationalHoffmann-La RocheGlaxoSmithKline

To order this report: Pathology Industry: PharmaPoint: Multiple Sclerosis - Current and Future Players

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs